Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Journal of veterinary internal medicine/ American College of Veterinary Internal Medicine
Volume 38 | Issue 4 (2024 Jul-Aug)

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.

J Vet Intern Med. 2024 Jul-Aug;38(4):2099 - 2119.
Stijn J M Niessen1, Hans S Kooistra2, Yaiza Forcada3, Charlotte R Bjørnvad4, Balazs Albrecht5, Franziska Roessner6, Esther Herberich7, Carla Kroh8
1 Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.; 2 Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.; 3 Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.; 4 Bjørnvad Consultancy, Vedbæk, Denmark.; 5 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; 6 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; 7 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; 8 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.

Abstract

BACKGROUND:Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia.
HYPOTHESIS:Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections.
ANIMALS:Client-owned diabetic cats (127 safety; 116 efficacy assessment).
METHODS:Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days.
RESULTS:On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference -11.8%; upper 1-sided 97.5% confidence interval, -∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin).
CONCLUSIONS AND CLINICAL IMPORTANCE:Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.

Keywords
antidiabetic; beta‐cell; compliance; feline diabetes mellitus; glucosuria; glucotoxicity; glycemic control; prospective clinical trial; sodium‐glucose cotransporter‐2 (SGLT2) inhibitor;

Article Tools:
   Medline
   Email to me

Grants:
Boehringer Ingelheim Animal Health

Archives Highlights:
Guide for nonswine practitioners to enhance swine disease diagnoses.
This review aims to help clinicians across the country that may not have an in-depth experience in swine medicine become more familiar with both common and novel pathogens, formulate a differential diagnosis based on the age of the animals and affected system (eg, respiratory, systemic, nervous, and enteric), select proper samples and laboratory testing, and interpret laboratory data to achieve a disease diagnosis in porcine patients.
Owner survey suggests cats may be undertreated for pain compared to dogs after an elective ovariohysterectomy or orchiectomy.
Analgesics were prescribed for 19 of 162 (12%) pets: 14 of 88 (16%) dogs and 5 of 74 (6.7%) cats. There was no difference in the prescription of analgesics between dogs and cats after ovariohysterectomy or orchiectomy. 15 of 19 owners reported their compliance in administering analgesics at 78.9%. Owners' subjective assessments showed that 24 of 86 (28%) dogs and 12 of 68 (17%) cats appeared painful at home.
Clinical characterization of a novel episodic ataxia in young working Cocker Spaniels.
The mean age at clinical onset was 4 months. Signs were acute and included episodic body swaying, titubation, cerebellar ataxia, wide-base stance, and hypermetria, all while mentation remained unaltered. Duration of episodes ranged from 30 minutes up to 24 hours, and their frequency varied from weekly to once every 5 months.
The Most Common Environmental Risk Factors for Equine Asthma-A Narrative Review.
The symptoms of equine asthma are typical of respiratory inflammations, and they include coughing, nasal discharge, and breathing difficulty even at rest in horses with severe asthma. BALF and tracheal wash analyses are the most popular methods of diagnosing equine asthma. Inadequate housing conditions undoubtedly increase the risk of asthma.
Retrospective cohort study on diseases and risk factors associated with death in hospitalized neonatal foals.
Most prevalent diseases were sepsis (43.9%), enteritis (14.0%), and omphalitis (9.0%). Case fatality rate was 33.3%. Neonatal sepsis significantly increased the risk of death.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Efficacy and safety of on...
Contact Us